Search

Összefoglaló. Az arthrogryposis–renalis diszfunkció–cholestasis (ARC) szindróma igen rossz prognózisú autoszomális recesszív kórkép. A három vezető tünethez társulhat központi idegrendszeri érintettség, siketség, cardiovascularis anomália (pitvari és kamrai sövényhiány), thrombocytafunkció-zavar, rekurrens szepszisek, ichthyosis, valamint súlyfejlődésben való elmaradás. A háromnapos újszülöttet neuromuscularis betegség gyanúja miatt vettük át a szülészeti intézményből. Fizikális vizsgálat során pes equinovarust és hypotrophiás küllemet tapasztaltunk. Kéthetes korában súlyos tubulopathia, valamint cholestasis igazolódott normális gamma-glutamil-transzferáz-szint mellett. A perifériás vérkenet vizsgálata során abnormális morfológiájú thrombocyták ábrázolódtak. Súlygyarapodást komplex felépített enteralis és parenteralis táplálás segítségével sem sikerült elérni. Három hónapos korára a gyermek súlya 15%-kal a születési súlya alatt volt. A kórkép szövődményeként ismétlődő bakteriális véráramfertőzés súlyosbította az állapotát. Az újszülött klinikai képe az ARC-szindrómának felelt meg. A kóroki gének szekvenálása során a VPS33B-génben homozigóta c.498+1G>T variáns igazolódott, mely igazolja a betegség fennállását. Orv Hetil. 2022; 163(2): 74–78. Summary. Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome is an autosomal recessive multisystem disorder that typically presents with arthrogryposis, renal tubular leak and neonatal cholestatic jaundice. It can be accompanied by nervous system abnormalities, deafness, structural cardiac defects, abnormal platelet morphology, recurrent sepsis, ichthyosis and failure to thrive. The three-day-old neonate was admitted for a suspected neuromuscular disorder. On examination, clubfoot, jaundice and hypotonia were found. Laboratory evaluation revealed tubulopathy and cholestasis with normal gamma-glutamyl transferase level. Peripheral blood smear evaluation revealed abnormally giant platelets. Despite the combined enteral and parenteral nutrition, the infant experienced severe failure to thrive. The phenotype of the presented neonate is consistent with ARC syndrome. Sequencing of the causal genes revealed a homozygous consensus splice site VPS33B mutation (c.498+1G>T), confirming the clinical diagnosis. Orv Hetil. 2022; 163(2): 74–78.

A primer hyperoxaluria ritka anyagcsere-betegség. A glioxilát anyagcserezavara miatt nagy mennyiségű oxalát keletkezik, amely – mivel rosszul oldódik – a szövetekben oxalátkicsapódáshoz, oxalosishoz vezet. Az oxalosis elsőként a veséket érinti, enyhébb formában urolithiasishoz, súlyos esetekben nephrocalcinosishoz és progresszív vesefunkció-romláshoz, végül végstádiumú veseelégtelenséghez vezet. A betegség típusát genetikai vizsgálattal lehet pontosan azonosítani. Klinikai megjelenése nagyon változatos. Enyhébb esetekben az oxaláttermelés csökkentése és kicsapódásának gátlása jelenthet terápiás lehetőséget, súlyosabb esetben vesepótló kezelésre lehet szükség. A betegség kóroki terápiáját egyelőre a májátültetés jelenti. Az oxalát kialakulásában kulcsszerepet játszó enzim RNS-interferencia útján történő gátlásán alapuló biológiai terápia új perspektívát jelenthet a betegség komplex kezelésében.

RNA modifications play a fundamental role in cellular function. Pseudouridylation, the most abundant RNA modification, is catalyzed by the H/ACA small ribonucleoprotein (snoRNP) complex that shares four core proteins, dyskerin (DKC1), NOP10, NHP2, and GAR1. Mutations in DKC1 , NOP10 , or NHP2 cause dyskeratosis congenita (DC), a disorder characterized by telomere attrition. Here, we report a phenotype comprising nephrotic syndrome, cataracts, sensorineural deafness, enterocolitis, and early lethality in two pedigrees: males with DKC1 p.Glu206Lys and two children with homozygous NOP10 p.Thr16Met. Females with heterozygous DKC1 p.Glu206Lys developed cataracts and sensorineural deafness, but nephrotic syndrome in only one case of skewed X-inactivation. We found telomere attrition in both pedigrees, but no mucocutaneous abnormalities suggestive of DC. Both mutations fall at the dyskerin–NOP10 binding interface in a region distinct from those implicated in DC, impair the dyskerin–NOP10 interaction, and disrupt the catalytic pseudouridylation site. Accordingly, we found reduced pseudouridine levels in the ribosomal RNA (rRNA) of the patients. Zebrafish dkc1 mutants recapitulate the human phenotype and show reduced 18S pseudouridylation, ribosomal dysregulation, and a cell-cycle defect in the absence of telomere attrition. We therefore propose that this human disorder is the consequence of defective snoRNP pseudouridylation and ribosomal dysfunction.

Összefoglaló. Az arthrogryposis-renalis diszfunkció-cholestasis (ARC) szindróma igen rossz prognózisú autoszomális recesszív kórkép. A három vezető tünethez társulhat központi idegrendszeri érintettség, siketség, cardiovascularis anomália (pitvari és kamrai sövényhiány), thrombocytafunkció-zavar, rekurrens szepszisek, ichthyosis, valamint súlyfejlődésben való elmaradás. A háromnapos újszülöttet neuromuscularis betegség gyanúja miatt vettük át a szülészeti intézményből. Fizikális vizsgálat során pes equinovarust és hypotrophiás küllemet tapasztaltunk. Kéthetes korában súlyos tubulopathia, valamint cholestasis igazolódott normális gamma-glutamil-transzferáz-szint mellett. A perifériás vérkenet vizsgálata során abnormális morfológiájú thrombocyták ábrázolódtak. Súlygyarapodást komplex felépített enteralis és parenteralis táplálás segítségével sem sikerült elérni. Három hónapos korára a gyermek súlya 15%-kal a születési súlya alatt volt. A kórkép szövődményeként ismétlődő bakteriális véráramfertőzés súlyosbította az állapotát. Az újszülött klinikai képe az ARC-szindrómának felelt meg. A kóroki gének szekvenálása során a VPS33B-génben homozigóta c.498+1GT variáns igazolódott, mely igazolja a betegség fennállását. Orv Hetil. 2022; 163(2): 74-78. Summary. Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is an autosomal recessive multisystem disorder that typically presents with arthrogryposis, renal tubular leak and neonatal cholestatic jaundice. It can be accompanied by nervous system abnormalities, deafness, structural cardiac defects, abnormal platelet morphology, recurrent sepsis, ichthyosis and failure to thrive. The three-day-old neonate was admitted for a suspected neuromuscular disorder. On examination, clubfoot, jaundice and hypotonia were found. Laboratory evaluation revealed tubulopathy and cholestasis with normal gamma-glutamyl transferase level. Peripheral blood smear evaluation revealed abnormally giant platelets. Despite the combined enteral and parenteral nutrition, the infant experienced severe failure to thrive. The phenotype of the presented neonate is consistent with ARC syndrome. Sequencing of the causal genes revealed a homozygous consensus splice site VPS33B mutation (c.498+1GT), confirming the clinical diagnosis. Orv Hetil. 2022; 163(2): 74-78.

RNA modifications play a fundamental role in cellular function. Pseudouridylation, the most abundant RNA modification, is catalyzed by the H/ACA small ribonucleoprotein (snoRNP) complex that shares four core proteins, dyskerin (DKC1), NOP10, NHP2, and GAR1. Mutations in DKC1, NOP10, or NHP2 cause dyskeratosis congenita (DC), a disorder characterized by telomere attrition. Here, we report a phenotype comprising nephrotic syndrome, cataracts, sensorineural deafness, enterocolitis, and early lethality in two pedigrees: males with DKC1 p.Glu206Lys and two children with homozygous NOP10 p.Thr16Met. Females with heterozygous DKC1 p.Glu206Lys developed cataracts and sensorineural deafness, but nephrotic syndrome in only one case of skewed X-inactivation. We found telomere attrition in both pedigrees, but no mucocutaneous abnormalities suggestive of DC. Both mutations fall at the dyskerin–NOP10 binding interface in a region distinct from those implicated in DC, impair the dyskerin–NOP10 interaction, and disrupt the catalytic pseudouridylation site. Accordingly, we found reduced pseudouridine levels in the ribosomal RNA (rRNA) of the patients. Zebrafish dkc1 mutants recapitulate the human phenotype and show reduced 18S pseudouridylation, ribosomal dysregulation, and a cell-cycle defect in the absence of telomere attrition. We therefore propose that this human disorder is the consequence of defective snoRNP pseudouridylation and ribosomal dysfunction.

Background Prevalence of fibroproliferative diseases, including chronic kidney disease is rapidly increasing and has become a major public health problem worldwide. Fibroproliferative diseases are characterized by increased expression of α smooth muscle actin (α-SMA) that belongs to the family of the six conserved actin isoforms showing high degree homology. The aim of the present study was to develop real-time PCRs that clearly discriminate α-SMA and ß-actin from other actin isoforms. Results Real-time PCRs using self-designed mouse, human and rat specific α-SMA or ß-actin primer pairs resulted in the specific amplification of the artificial DNA templates corresponding to mouse, human or rat α-SMA or ß-actin, however ß-actin showed cross-reaction with the housekeeping γ-cyto-actin. We have shown that the use of improperly designed literary primer pairs significantly affects the results of PCRs measuring mRNA expression of α-SMA or ß-actin in the kidney of mice underwent UUO. Conclusion We developed a set of carefully designed primer pairs and PCR conditions to selectively determine the expression of mouse, human or rat α-SMA and ß-actin isoforms. We demonstrated the importance of primer specificity in experiments where the results are normalized to the expression of ß-actin especially when fibrosis and thus increased expression of α-SMA is occur.

The short arm of chromosome 16 (16p) is enriched for segmental duplications, making it susceptible to recurrent, reciprocal rearrangements implicated in the etiology of several phenotypes, including intellectual disability, speech disorders, developmental coordination disorder, autism spectrum disorders, attention deficit hyperactivity disorders, obesity and congenital skeletal disorders. In our clinical study 73 patients were analyzed by chromosomal microarray, and results were confirmed by fluorescence in situ hybridization or polymerase chain reaction. All patients underwent detailed clinical evaluation, with special emphasis on behavioral symptoms. 16p rearrangements were identified in 10 individuals. We found six pathogenic deletions and duplications of the recurrent regions within 16p11.2: one patient had a deletion of the distal 16p11.2 region associated with obesity, while four individuals had duplications, and one patient a deletion of the proximal 16p11.2 region. The other four patients carried 16p variations as second-site genomic alterations, acting as possible modifying genetic factors. We present the phenotypic and genotypic results of our patients and discuss our findings in relation to the available literature. info:eu-repo/semantics/publishedVersion

Gonadal dysgenesis (GD) is a rare cause of differences of sex development (DSD) with highly variable clinical and genetic conditions. Although identification of the causative genetic alterations can offer a clearer prognosis and personalized management to patients, more than 50% of the DSD cases still do not have an accurate genetic diagnosis. NR5A1 (previously known as SF-1), is a transcriptional regulator of genes required for normal development and functional maintenance of the gonads and the adrenal glands. Nucleotide sequence variants of the NR5A1 gene have been reported in numerous patients with GD with or without adrenal failure, however, microdeletion or partial deletion in the NR5A1 gene have been described only in a few GD cases. In this case study, we present a subject with female phenotype, mild clitoromegaly, partial GD and normal adrenal function. Cytogenetic analysis revealed a 46,XY SRY + karyotype. Microarray analysis did not identify pathogenic copy number variations, nor did panel sequencing of the most common DSD genes. Subsequently, multiplex ligation-dependent probe amplification (MLPA) was performed to test for small deletion/duplication of the most frequently affected genes associated with GD. Using this method, we have identified a novel heterozygous deletion involving exons 5 and 6 of the NR5A1 gene as the cause of abnormal sexual development of the patient. This report expands our knowledge about the range and pathogenetic role of NR5A1 mutations associated with partial gonadal dysgenesis in 46,XY DSD. Furthermore, our data emphasises the indispensable role of MLPA in the diagnosis of DSD with unclear etiology.

We report on a sibling pair with the EPG5 c.1007A > G mutation who developed a severe form of Vici syndrome and died in infancy. The c.1007A > G (p.Gln336Arg) mutation, affecting the penultimate nucleotide and the splicing of exon 2 is the most common mutation of EPG5 and is typically associated with a less devastating prognosis: cardiomyopathy and cataract are less frequent consequences and the median survival time is 78 months compared to an overall median survival of 42 months. The less severe course related to c.1007A > G was formerly explained by the preserved canonical splicing in 25% of the transcripts. In contrast, we found the messenger RNA encoded by the c.1007A > G allele to be absent, explaining the severe course of the disease. This family provides another example of phenotypic variability related to a differential splicing.

Background: Nephronophthisis, an autosomal recessive nephropathy, is responsible for 10% of childhood chronic renal failure. The deletion of its major gene, NPHP1, with a minor allele frequency of 0.24% in the general population, is the most common mutation leading to a monogenic form of childhood chronic renal failure. It is challenging to detect it in the heterozygous state. We aimed to evaluate the sensitivity and the specificity of the quantitative multiplex PCR of short fluorescent fragments (QMPSF) in its detection. Methods: After setting up the protocol of QMPSF, we validated it on 39 individuals diagnosed by multiplex ligation-dependent probe amplification (MLPA) with normal NPHP1 copy number (n=17), with heterozygous deletion (n=13, seven parents and six patients), or with homozygous deletion (n=9). To assess the rate of the deletions that arise from independent events, deleted alleles were haplotyped. Results: The results of QMPSF and MLPA correlated perfectly in the identification of 76 heterozygously deleted and 56 homozygously deleted exons. The inter-experimental variability of the dosage quotient obtained by QMPSF was low: control, 1.05 (median; range, 0.86−1.33, n = 102 exons); heterozygous deletion, 0.51 (0.42−0.67, n = 76 exons); homozygous deletion, 0 (0−0, n = 56 exons). All patients harboring a heterozygous deletion were found to carry a hemizygous mutation. At least 15 out of 18 deletions appeared on different haplotypes and one deletion appeared de novo. Conclusions: The cost- and time-effective QMPSF has a 100% sensitivity and specificity in the detection of NPHP1 deletion. The potential de novo appearance of NPHP1 deletions makes its segregation analysis highly recommended in clinical practice.

Physical, chemical and microbiological stability of total parenteral nutrient (TPN) admixtures was studied as a function of storage time and temperature. Particle size analysis and zeta potential measurements were carried out to evaluate the possible changes in the kinetic stability of the emulsions as a function of storage time and temperature. The concentration changes of the applied additives, those of the ascorbic acid and L-alanyl-L-glutamine, were also determined under different storage conditions. Our results indicate that there were no significant differences in the particle size and zeta potential values of admixtures stored at the three examined temperatures. The best results were obtained in the case of admixtures stored at 30°C temperature. Rapid decomposition of vitamin C was found while the glutamine showed adequate stability as a function of storage time and temperature. According to the results of the physicochemical examinations 10-day storage period of this type of TPN admixtures can be accepted at room temperature. Their storage does not require refrigeration (2-8°C) thus they can be administered without special preheating ensuring better physiological tolerance. Ascorbic acid can be added to the system preceding the administration to the patient because of its rapid decomposition.

A method has been developed to determine furanic compounds in insulating oil matrix using liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. The examined samples were provided from model experiments and also from several high voltage functioning transformers. To increase sensitivity of the method six furanic compounds (determined by model experiments) were quantified by selected ion monitoring, and quantitation was based on the marker peaks. Oil samples were prepared using solid phase extraction. The results are suitable for evaluation of model experiments and also to solve problems of calibration. From extracts of oil samples taken from functioning transformers cellulose depolymerization products have been identified, and their amounts were found to be valuable in assessing the condition of the transformer (fault diagnosis). © 1998 John Wiley & Sons, Ltd.

The pathogenicity of the NPHS2 homozygous p.R229Q variant in steroid-resistant nephrotic syndrome (SRNS) is doubtful. While it has been reported in unaffected controls, it is enriched in patients with SRNS, suggesting pathogenicity. A family with three members homozygous for the NPHS2 p.R229Q variant is presented: a 37-year-old patient who was diagnosed with proteinuria at age 7 months, focal segmental glomerulosclerosis (FSGS) at age 20 years, and end-stage renal disease (ESRD) at age 33 years, his 59 year-old father and his 40 year-old brother, both unaffected with no proteinuria. The affected son also harbors a heterozygous de novo, truncating PAX2 mutation (c.76dupG, p.V26Gfs*28), which can explain his chronic renal failure but which is rarely associated with FSGS. This family provides further evidence that homozygous p.R229Q in itself may not cause FSGS. Nevertheless, the rare association of FSGS to a PAX2 mutation may reflect the modifier effect of p.R229Q in the homozygous state. Such a modifier effect can also explain its enrichment in SRNS patients. Patients with homozygous p.R229Q should be screened for the causative mutation in a second gene.

Authors summarized the etiology of convulsions in neonatal period and infancy (hypoxia, intracranial hemorrhage, infections of central nervous system, metabolic background, chromosomal abnormalities, brain developmental abnormalities, benign neonatal convulsions, benign neonatal familial convulsions, drug withdrawal, inborn error of metabolism). They suggest screening examinations after convulsion, summarized the basic principle of tandem examination and review a proposal at suspicion of inborn error of enzyme defects (aminoacidemias, defects of fatty acid oxidation, organic acidemias). They present case history of two patients suffered in extraordinary inborn error of enzyme defect (SCO2 gene mutation, propionic acidemia). Diagnosis originated in Helm P61 Hospital (settlement Madarász Hospital) with a Hungarian and international cooperation.